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Abstract 3 
Generation of human organoids from induced pluripotent stem cells (iPSCs) offers exciting 4 
possibilities for developmental biology, disease modelling and cell therapy. Significant advances 5 
towards those goals have been hampered by dependence on animal derived matrices (e.g. 6 
Matrigel), immortalized cell lines and resultant structures that are difficult to control or scale. To 7 
address these challenges, we aimed to develop a fully defined liver organoid platform using 8 
inverted colloid crystal (ICC) whose 3-dimensional mechanical properties could be engineered to 9 
recapitulate the extracellular niche sensed by hepatic progenitors during human development. 10 
iPSC derived hepatic progenitors (IH) formed organoids most optimally in ICC scaffolds 11 
constructed with 140 µm diameter pores coated with type I collagen in a two-step process 12 
mimicking liver bud formation. The resultant organoids were closer to adult tissue, compared to 13 
2D and 3D controls, with respect to morphology, gene expression, protein secretion, drug 14 
metabolism and viral infection and could integrate, vascularize and function following 15 
implantation into livers of immune-deficient mice. Preliminary interrogation of the underpinning 16 
mechanisms highlighted the importance of TGFβ and hedgehog signalling pathways. The 17 
combination of functional relevance with tuneable mechanical properties leads us to propose this 18 
bioengineered platform to be ideally suited for a range of future mechanistic and clinical 19 
organoid related applications.  20 
Keywords 21 
Biomimetic materials; liver stem cells; bioengineering; organogenesis. 22 
1. Introduction 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
Induced pluripotent stem cells offer exciting new possibilities in developmental biology, disease 1 
modeling and transplantation. Comprehensive realization of that promise is likely to require 2 
consolidation with other emerging technologies such as 3D cell culture. Along those lines, 3 
hepatic progenitor cells derived from iPSCs [1] and primary tissue [2] were recently shown to 4 
form “Organoids” (self-organizing miniaturized 3D structures resembling liver tissue) following 5 
3D culture initiated by Matrigel. Organoid generation using Matrigel has similarly been 6 
demonstrated across a broad range of tissue types including intestine, kidney and brain [3-5], 7 
underlining the importance of this novel approach across the stem cell field. Downstream 8 
applications are however limited by the use of Matrigel which is poorly characterized, highly 9 
variable and of mouse origin [6]. A bioengineered substitute is therefore essential and was 10 
recently reported for intestinal organoid generation [7]. A similar bottom up engineering 11 
approach for liver organoid production is urgently needed. We recently developed a novel 12 
hepatocyte culture system composed of a 3D-hexagonally arrayed inverted colloidal crystal 13 
(ICC) scaffold [8]. In comparison to other 3D culture systems, the ICC boasts several 14 
advantages. These include being made from an FDA approved material, polyethylene glycol 15 
(PEG), that can be functionalized with select ECM proteins or varied in mechanical stiffness, a 16 
highly uniform architecture which incorporates size-selectable pores to facilitate tissue 17 
interconnection across the whole module whilst retaining uniform nutrient penetration to all cells 18 
and finally, being transparent to provide an easy means of viewing cells and intra-cellular 19 
fluorescence over time. Exploiting these properties, we were able to facilitate induction of 20 
organoid structures with advanced liver function in primary human fetal liver cells cultured in 21 
ICC’s [9]. Lack of donor material, ethical constraints and biological heterogeneity however make 22 
further progress difficult with human fetal cells. We therefore turned to the recently established 23 
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technology of human iPSC-derived hepatocytes [10][11], as a good biological approximation to 1 
human fetal liver cells but not limited by the same constraints cited above, to explore their 2 
potential for organoid generation. 3 
2. Materials & methods 4 
2.1. Study design 5 
The overall objective of this study was to test whether organoids bioengineered in ICC scaffolds 6 
exhibited a more physiologically relevant liver phenotype compared to conventional 2D or 3D 7 
(Matrigel and Spheroid) models. iPSC-derived hepatic progenitors (IH) differentiated from the 8 
same parental line were therefore matured in four different in vitro models (ICC, 3D Matrigel, 9 
Spheroid and 2D) for 14 days and compared. Measurement techniques to compare the three 10 
models were designed to characterize two major endpoints: morphology (organoid formation) 11 
and function (gene expression, protein expression, liver specific functions and in vivo behavior). 12 
In transplant experiments, littermate animals were randomly assigned to experimental groups and 13 
analysis of samples was performed blindly. Studies were repeated at least three times.  14 
2.2. Cells 15 
 All human tissues were collected with informed consent following ethical and institutional 16 
guidelines. Freshly isolated hepatocytes were obtained from Triangle Research Labs (TRL) and 17 
Human Developmental Biology Resource (HDBR) University College London (UCL). Fetal 18 
hepatocytes were obtained from 16-20 week old fetuses (HDBR), dissociated as previously 19 
described [12]. Three different human iPSC lines were used to generate hepatic progenitors (IH) 20 
for these experiments: [1], [10], (https://stemcells.nindsgenetics.org/)[11] the latter of which is 21 
considered to be of ‘clinical grade’ and thereby potentially suitable for future human therapy.  22 
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2.3. ICC fabrication 1 
Sacrificial crystal lattices were constructed on a rhombus PDMS mold with 17mmx15mm 2 
diagonal lengths and 2mm depth using polystyrene beads with diameter of 40µm, 60µm, 100µm, 3 
or 140µm (Duke Scientific) and annealed under 140˚C for 1.5 hours. Lattices were then 4 
infiltrated with precursor solution of 50 %w/v polyethylene glycol-diacrylate (PEGDA, Alfa 5 
Aesar), 10 %w/v acrylate-PEG-N-hydroxysuccinimide (Laysan Bio Inc, AL) and 1 %w/v 6 
photoinitiator (Irgacure® 2959, BASF, Switzerland) in DI water. The precursor solution 7 
underwent free-radical induced polymerization under 75 W xenon ultraviolet (UV) light source 8 
(Oriel Instruments, Mountain View, CA) for 10 min. After polymerization, the polystyrene 9 
sacrificial lattice was removed by tetrahydrofuran treatment for two hours. The resulting ICC 10 
hydrogel scaffolds were equilibrated in deionized water and conjugated with appropriate ECM 11 
proteins, such as 100µg/mL Collagen I (Col-I, Sigma), 50µg/mL Fibronectin (Fn, RnD), and 12 
10µg/mL Laminin 521 (Ln-521, Biolamina) (Fig. 1A). The final tubular ICC scaffolds for 96 13 
well plate format culture were created using 6mm biopsy punch. 14 
2.4. iPSC-derived liver organoid culture  15 
iPSC-derived hepatic progenitors (IH) were generated using our established protocol (Fig. 1B) 16 
[13]. To generate iPSC liver organoids, we suspended approximately 0.5x106 IH cells in 17 
Hepatozyme medium (Life Technologies), supplemented with Oncostatin M 0.01 µg/ml 18 
(Peprotech) and Hepatocyte Growth Factor 0.05 µg/ml (Peprotech) with the final cell density of 19 
125x106 cells/ml (Fig. 1C). Approximately 4µl cell suspension was then pipetted onto top and 20 
bottom surfaces of partially dehydrated ICC scaffolds and placed in an incubator for 30 min 21 
without media to minimize cell loss and maximize cell attachment. Cell-laden ICC scaffolds 22 
were then transferred to a new 96-well plate for culture and media were refreshed at four hours 23 
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post-seeding to remove excessive cells that are not attached to surface or established cellular 1 
clusters. Cells were left for a further 14 days to mature. Media was refreshed every two days. 2D 2 
controls were generated using IH cells seeded into standard 48 well plate tissue culture plastic 3 
plates coated with the same ECM proteins and cultured with the same reagents as used for ICC 4 
culture. 5 
2.5. Generation of IH-spheroids  6 
A single cell suspension of IH was prepared and 0.3x106 cells were seeded per well of a 24-well 7 
Aggrewell-400 (STEMCELL Technologies, Vancouver, Canada).  Aggrewell plates were 8 
prepared as recommended by the supplier.  Centrifugation at 200G for 3 minutes was carried out 9 
to deposit cells into the microwells of the plate. 10 
2.6. Immunofluorescence staining and imaging 11 
After fixation with 4% paraformaldehyde, cells were blocked and permeabilized in 1% w/v 12 
bovine serum albumin (BSA, Sigma-Aldrich), 10% donkey serum (Life Technologies) and 0.1% 13 
Triton) for 30 min at RT. For nuclear antigens, cells were treated with 0.5% Triton (Sigma-14 
Aldrich), then primary antibodies, CTNNB (mouse, 1:100; bdbiosciences), CK19 (rabbit, 1:500; 15 
abcam), HNF4a (rabbit, 1:100; abcam), AFP (mouse, 1:100; abcam) and ALB (goat, 1:100; 16 
Bethyl), ASGR1 (mouse, 1:100; Thermo Fisher Scientific), COL1 (rabbit, 1:500; abcam), 17 
Vimentin (rabbit, 1:200; abcam); CD44 (mouse, 1:200 abcam), CD31 (rabbit, 1:50; abcam); Col-18 
X (mouse, 1:250; abcam), MRP2 (mouse, 1:200; abcam), ZO-1 (mouse, 1:100; abcam), CD26 19 
(rabbit, 1:100; abcam), Pan-Cadherin (mouse, 1:100; Sigma), Claudin 1 (rabbit, 1:100; abcam), 20 
Occludin (mouse, 1:100; abcam), Stem121 (mouse, 1:100; Cellartis), phosphor-SMAD2/3 21 
(rabbit, 1:100; Cell signaling technology) and GLI1 (rabbit, 1:100; abcam) were applied for 22 
overnight at 4˚C. After washes, cells were then incubated with Alexa 647, Alexa 568, Alexa 488 23 
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conjugated secondary antibodies or 488-Phalloidin (1:250; Life Technologies). Samples were 1 
counterstained with DAPI (NucBlue, Life Technologies). Confocal micrographs were captured 2 
using Nikon Ti spinning disk confocal microscope equipped with Andor Neo camera and images 3 
were processed by NIS-element software. 4 
2.7. Bright field imaging  5 
Bright field imaging was captured using Leica DMIL LED equipped with Leica DFC3000 G 6 
camera and images processed by LAS X software. 7 
2.8. Live/Dead staining  8 
Fluorescine diacete (FDA) (Sigma-Aldrich, St. Louis, USA) and cell-impermeant ethidium 9 
homodimer-1 (EthD-1) (Thermo Fisher Scientific, Waltham, USA) were used as recommended 10 
by the supplier for staining of viable and dead cells.  Spheroids and alginate encapsulated cells 11 
were incubated in 4µM EthD-1 for 35 minutes, washed with Hank’s Balanced Salt Solution 12 
(HBSS) containing calcium (Thermo Fisher Scientific, Waltham, USA), then incubated in 13 
50µg/ml FDA for 90 seconds, and finally washed 5 times with HBSS before imaging 14 
2.9. Cell number quantification:  15 
Double stranded DNA was collected, quantified and interpolated from standard curve plotted 16 
using a range of known cell number as illustrated by Quant-iTTM PicoGreenTM dsDNA Assay Kit 17 
(ThermoFisher Scientific) 18 
2.10. Human albumin Enzyme-linked Immunosorbent Assay (ELISA)  19 
Albumin secretion of all different cell types was assessed using the Human Albumin 20 
Quantitation Set (Bethyl Laboratories Inc) following manufacturer’s instructions. 21 
2.11. Immuno-histochemistry staining and imaging 22 
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IH-ICC or animal explants were fixed in 10% formalin buffer saline for two days then 1 
dehydrated and paraffin wax infiltrated using Excelsior™ AS Tissue Processor. After embedded, 2 
sectioned (5µm), and stained using Mouse and Rabbit Specific HRP/AEC (ABC) Detection IHC 3 
Kit (abcam) using antibody CK19 (rabbit, 1:200; abcam), EPCAM (mouse, 1:200; abcam), ALB 4 
(mouse, 1:100; abcam) and CD31 (mouse, 1:100; Dako) then counterstained with haematoxylin 5 
(abcam). Mounted slides were imaged using NanoZoomer (Hamamatsu). 6 
2.12. Image analysis 7 
To analyse the confluency and cluster morphology of cells in ICC, selected images of F-actin 8 
staining were reconstructed using maximum intensity projection. The confluency index 9 
=(Cc/Cp*100%) is introduced to quantify the proportion of the ICC surface covered by cell 10 
attachment by measuring the circumference of cell lining (Cc) over the overall circumference of 11 
pores in ICC (Cp). The cluster index = (Kc/Kp*100%) is introduced to quantify the number of 12 
cell cluster in each pore (Kc) against the total number of pores (Kp) in the frame. 13 
2.13. Fluorescence-activated cell sorting (FACS) staining and analysis  14 
Cells were dissociated from organoid or 2D culture using TrypLE reagent (Thermo Fisher 15 
Scientific) and stained using the same condition as immunofluorescence staining protocol stated 16 
above. Flow analysis performed using FACSCanto II (BD) and analyized using FlowJo (LLC). 17 
2.14. Quantitative real-time PCR (RT-qPCR) analysis  18 
Total RNA was harvested using TRIZOL reagent (Sigma), treated with DNase (Promega) and 19 
phenol/chloroform purified. For each sample 0.5 µg of total RNA was reverse transcribed using 20 
SuperScript VILO cDNA Synthesis kit (Thermo Fisher Scientific). A typical RT-PCR reaction 21 
contained 10ng of sample cDNA, 0.0075µl of individual forward and reverse primer each at 22 
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100µM stock, 5µl Taqman Universal Master mix (Applied Biosystems), 1ul Taqman target 1 
probe (supplementary Fig. 5) and made up to 10µl with nuclease-free water. Real time PCR 2 
reactions were amplified for 40 cycles on a CFX384 Touch™ Real-Time PCR Detection System 3 
(Biorad) in triplicate and normalized to ACTB in the same run.  4 
2.15. Heat map generation, gene set enrichment analysis, functional network analysis and top 5 
canonical pathway analysis:  6 
Heat maps were generated from Bulk RNAseq data collected from three Human Fetal Livers, 7 
three Human Adult Livers and three iPSC-derived hepatocytes harvested at definitive 8 
endodermal stage from the BOB cell line. The three fetal livers included 14pcw, 16pcw and 9 
20pcw. The three adult Livers were Female 18yrs, Male 43yrs and Male 13yrs.  RNA was 10 
extracted using TRI reagent. Starting with 1ug input total RNA, Ribosomal RNA was removed 11 
using Ribo-Zero Gold rRNA Removal kit (Illumia). Sequencing libraries were prepared using 12 
NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina (N.E.B) using 100ng rRNA 13 
depleted sample and sequenced on a HiSeq 2500 system in Rapid run mode (Illumina) following 14 
a standard protocol. All libraries generated between 15 and 25M reads. Reads were mapped to 15 
GRCh38 reference genome using Bowtie2. Raw counts and normalized gene expression was 16 
generated using HT-Seq and DESEq2 packages respectively. Heat map was generated using R 17 
(http://www.R-project.org) (R Development Core Team, 2008). Heat maps represent average 18 
DESEq2 normalized gene expression values of three independent biological samples. Gene set 19 
enrichment analysis was performed on normalized RNA sequencing gene expression data 20 
through GSEA software27,28 run using the hallmark MSigDB gene set collections. To examine 21 
the role of IH-ICC organoid in cell polarity and bile acid synthesis and metabolism, we cross-22 
referenced the differential gene expression with the Gene Ontology (GO) annotations and predict 23 
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the protein interactions networking using Search Tool for the Retrieval of Interacting Genes 1 
(STRING). Top canonical pathways analysis was performed using Ingenuity Pathway Analysis 2 
(IPA) (Qiagen). 3 
2.16. GLuc HCVcc infection and analysis 4 
GLuc HCVcc is a full length Gaussia luciferase reporter virus Jc1FLAG2 (p7-nsGluc2A)35 5 
infectious Jc1 genome that allows us to monitor viral infection in real time. Knock down HCVcc 6 
is the corresponding polymerase-defective mutant that inhibits viral replication. Respective viral 7 
stocks were prepared using electroporation on Huh 7.5 cells as described [14]. Infectious titers of 8 
HCVcc inocula were determined using Huh 7.5 cells as described. Cultures were inoculated for 3 9 
hours with HCVcc then washed extensively with PBS and fed with culture media. 10 
2.17. Cholyl-lysyl-fluorescein (CLF) transportation 11 
5µM CLF (Corning) was incubated with cultures treated with 10µM Troglitazone (TGZ, Sigma) 12 
and 0.02% DMSO vehicle control for 45min. The cultures were then washed five times with 13 
PBS and incubated in culture media for 30min before confocal imaging. For CLF quantification, 14 
cultures where treated by cell lysis buffer (Sigma) and fluorescence intensity was measured 15 
using plate reader. 16 
2.18. Animal experiments 17 
All animal experiments were performed in accordance with UK Home Office regulations (UK 18 
Home Office Project License number PPL 70/8702). Immunodeficient NOD.Cg-Prkdcscid 19 
Il2rgtm1Wjl/SzJ (NSG) mice which lack B, T and NK lymphocytes were bred in-house with food 20 
and water available ad libitum pre- and post-procedures. A mix of male and female animals were 21 
used, aged approximately 6-8 weeks. An incision was made in the capsule of the caudate lobe of 22 
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the liver and a ‘pocket’ was created by raising a flap of capsule on either side of the incision. The 1 
scaffold was slid into the pocket and covered by the capsular flaps. The left lobe of the liver was 2 
then allowed to cover the site of the transplant.   3 
2.19. Statistical Analysis 4 
N in the paper represents the number of biological replicates of each batch of liver specific 5 
differentiation performed using three iPSC lines. Statistical significance (p < 0.05) was 6 
determined by using Student’s T-test (assume Gaussian distribution, two-tailed) or One-way 7 
ANOVA followed by Tukey’s posthoc test. . 8 
3. Results  9 
3.1. iPSC-derived hepatic progenitors (IH) form organoids analogous to fetal liver derived 10 
primary cells following culture in ICC scaffolds  11 
Human fetal liver cells seeded into ICC scaffolds with the 140µm pore size and type I collagen 12 
(Col-I) coating attach as a single cell layer (Phase I – days 0 to 5 post-seeding) before organising 13 
into morphologically stable, interconnected clusters (Phase II - days 7 post-seeding onward) 14 
(Fig. 1C). The resultant 3D structure resembles a mini-liver or hepatic ‘organoid’ with 15 
demonstrated advanced liver function [9]. We therefore hypothesized that organoid formation 16 
was critically dependent upon the translation of specific ‘cell-matrix’ and ‘cell-cell’ signals by 17 
hepatic progenitors in a manner which could be recapitulated using iPSC-derived progenitors 18 
(IH) (Supplementary Fig. 1). To test this hypothesis, we therefore engineered a library of ICC 19 
scaffolds to evaluate the effects of selected extracellular matrix protein (ECM) coatings and pore 20 
sizes on IH-organoid forming ability (Fig. 2). Of the ECM coatings tested, only cells seeded into 21 
Col-I were able to attach and self-organize into interconnected clusters throughout the scaffold as 22 
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observed with primary fetal progenitors (Fetal) (Fig. 2A-C, Supplementary Fig. 2). Cells 1 
seeded into fibronectin (Fn) attached but failed to establish confluency whilst cells seeded into 2 
laminin-521 (Ln-521) attached and remained as such throughout the culture. The observed 3 
organoid forming ability was matched by functional parameters of liver tissue such as albumin 4 
secretion and hepatic gene expression (Fig. 2D and Supplementary Fig. 3). Having established 5 
the optimal ECM coating, we next went on to assess the effects of cell-cell interaction by testing 6 
type I collagen coated ICC’s composed from different pore sizes. Accordingly, a 140µm pore 7 
size was found to be optimal for organoid formation based on morphology and again confirmed 8 
by hepatic function and gene expression (Fig. 2E-H). Through this extensive series of 9 
experiments, we observed IH seeded into type I collagen coated ICC scaffolds of 140 µm pore 10 
size best replicated the results seen with primary fetal liver cells with minimal cell lost and death 11 
(Supplementary Fig. 4-5). Importantly, the two-phase process of organogenesis was observed 12 
only with IH and primary fetal cells but did not occur with primary adult or cancer-like 13 
hepatocytes (Huh 7.5 and HepG2) (Supplementary Fig. 6). 14 
3.2. IH-ICC derived organoids demonstrate morphological and transcriptomic characteristics of 15 
human liver 16 
To evaluate the anatomical similarity between organoids derived from iPSC-hepatic progenitors 17 
cultured in ICC scaffolds (IH-ICC) and human liver, we first used a combination of 18 
histochemical and immunofluorescence staining to characterise the organoid tissue across the 19 
two phases of organogenesis previously described (Fig. 3A-B and Supplementary Fig. 7-10). 20 
In Phase I, hepatic progenitor markers such as keratin 19 (CK19), epithelial cell adhesion 21 
molecule (EPCAM) and alpha-fetoprotein (AFP) proteins were expressed in cells lining the 22 
circumference of the scaffold’s pores. Following onset of organogenesis in Phase II, these 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
(CK19, EPCAM, AFP, EdU) +ve progenitor cells were retained at the periphery of the organoid, 1 
with more mature cells, characterised by protein expression of asialoglycoprotein receptor 1 2 
(ASGR1), albumin (ALB), and hepatocyte nuclear factor 4-alpha (HNF4A), forming and 3 
remodelled by the cell secreted type I collagen (Col-I) at the centre. These data were then 4 
validated quantitatively using flow cytometry (Fig. 3C) and by RT-PCR for gene expression 5 
(Fig. 3D), allowing us to conclude that organoids became established with unique cellular 6 
arrangement in a structure reminiscent of the hepatic buds seen in embryonic [15] and 7 
regenerating human liver tissue [16]. This anatomical distribution was not observed when IH 8 
were cultured in Matrigel, the current gold standard in the field, or the conventional 3D spheroid 9 
model. Embedding in Matrigel, IH established lumen-containing colonies, expressing mature 10 
hepatic markers (Supplementary Fig. 11). On the contrary, IH formed solid cell clusters in 11 
spheroid model with more mature cells segregated on the outer layer (Supplementary Fig. 12). 12 
Both Matrigel and spheroid models demonstrated functional properties (protein secretion and 13 
metabolic activity) significantly higher compared to 2D culture but notably not significantly 14 
higher than in ICC culture (Supplementary Fig. 13). 15 
Having validated the organoid structure in our new bioengineered platform, we next 16 
sought to characterize the global transcriptomic changes during the different phases of 17 
organogenesis using RNA-seq. To do this, organoids were compared to iPSC derived definitive 18 
endoderm (DE), 2D cultured IH, primary adult and primary fetal hepatocytes. Principle 19 
component analysis (PCA) on DE, 2D, ICC, fetal and adult samples (Fig. 4A) shows that IH 20 
have a distinct transcriptional phenotype when cultured in ICC over 2D conditions. A liver-21 
specific gene-set of 296 genes were selected to perform unbiased hierarchical clustering and 22 
visualized by heatmap. The unbiased hierarchical clustering revealed that the liver-specific 23 
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transcriptional signature of organoids was positioned in the cluster next to adult and fetal liver, 1 
with higher similarity to fetal than adult, whereas 2D cells clustered next to DE (Fig. 3E). 2 
Overall 489 genes were found to be significantly upregulated in both organoid and 2D samples, 3 
with 1349 and 179 genes uniquely upregulated in organoid and 2D systems respectively (Fig. 4 
4B). Gene set enrichment and Ingenuity Pathway (IPA) analysis of the upregulated genes 5 
revealed some liver-specific functions such as xenobiotic and bile acid metabolism to be 6 
enriched in both organoid and 2D platforms (Supplementary Fig. 14 and Supplementary 7 
Table 1 and 2) but the majority of liver-specific functions such as cholesterol homeostasis, 8 
glycolysis, fatty acid metabolism and protein secretion were found to be uniquely enriched in IH-9 
ICC. The top 18 upregulated organoid specific hepatic genes were validated by qPCR 10 
(Supplementary Table 3 and Fig. 4C). 11 
Cumulatively, these data confirm our previous morphological observations suggesting IH 12 
derived progenitors seeded into ICC scaffolds form organoid structures whose transcriptomic 13 
and protein expression profiles resemble human liver structures.  14 
3.3. IH-ICC organoids are functionally closer to human liver 15 
Upon extended interrogation, we discovered that IH-organoids are functionally more advanced 16 
than the 2D model in albumin production and basal activities of drug metabolizing cytochrome 17 
P450 isoforms CYP3A4 and CYP2C9 (Fig. 5A and B). Similarly, capability for transporting bile 18 
salts also appeared more advanced. Hepatic polarity proteins critical for the structure of bile 19 
canaliculi such as multidrug resistance protein 2 (MRP2), tight junction protein 1 (ZO-1), CD26 20 
and pan-cadherin were all expressed (Fig. 5C and Supplementary Fig. 15). Bile salt efflux was 21 
then validated through uptake and accumulation of synthetic bile acid, cholyl-lysyl-flourescence 22 
(CLF), in bile canaliculi-like regions (Fig. 5D). The ability of organoids to retain CLF was 23 
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eliminated when treated with the BSEP inhibitor, Troglitazone (TGZ), as indicated by 1 
fluorescence measurement (Fig. 5E).  2 
 The cell polarity and bile acid secretory function of organoid was further validated by 3 
cross-referencing the uniquely upregulated differentially expressed genes in ICC with GO 4 
categories (GO 0007163: establishment or maintenance of cell polarity; GO 0000902: cell 5 
morphogenesis; GO 0007010: cytoskeleton organization; GO 0006699: bile acid biosynthetic 6 
process and GO 0008206: bile acid metabolic process) followed by functional network analysis 7 
using STRING on selected enriched gene sets (Fig. 5F and Supplementary Fig. 16-18) [17]. 8 
The 28 genes uniquely upregulated in organoids could be assigned to the key KEGG pathways 9 
such as regulation of actin cytoskeleton, focal adhesion and tight junction required for cell 10 
polarization (Fig. 5G).  11 
3.4. IH-ICC organoids are suitable for disease modelling and form vascularised tissue following 12 
transplantation 13 
Next, to test the ICC organoid’s suitability for disease modeling we investigated whether 14 
organoids expressed HCV host factors and were susceptible to HCV infection. Transcriptional 15 
analysis revealed expression of HCV host factors were enriched in organoids and more closely 16 
resembled the expression signature of primary hepatocytes (Fig. 6A). This included genes 17 
responsible for HCV entry such as claudin 1 (CLDN1) occludin (OCLN) scavenger receptor, 18 
class B, type 1 (SCARB1), CD81, low-density lipoprotein receptor (LDLR) and heparin sulfate 19 
glycoprotein (HSGP). In addition, a wide range of apoliproteins responsible for packaging and 20 
interacting with viral particles were highly expressed [18]. Immunofluorescence staining showed 21 
claudin 1 and occludin appear to localize at the interface of cell-cell junctions, similar to ZO-1 22 
and MRP2 (Fig. 6B and Supplementary Fig. 19). These results are in agreement with the 23 
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claudin 1 distribution seen in HepG2 and Huh-7 cell models permissive to HCV entry [19, 20]. 1 
We next infected organoids with genotype 2a HCV reporter virus expressing secreted Gaussia 2 
luciferase (HCVcc) and knock-down HCVcc (kd-HCVcc) which is incapable of replication and 3 
acts as a negative control. Luciferase signal was only detected in organoids inoculated with 4 
HCVcc cultures, whilst 2D cells and kd-HCVcc inoculated samples failed to exhibit detectable 5 
signal (Fig. 6C). 6 
Having confirmed the organoid’s preferential suitability for drug metabolism and disease 7 
modelling we next sought to explore the effects of in vivo transplantation. A pocket on the 8 
caudate lobe of murine liver was created by making an incision in the liver capsule. Organoids 9 
were placed into this pocket and sandwiched in place between the left lobe and the lower lateral 10 
lobe in order to achieve a bona fide homeostatic environment (Fig. 6D). After 4 weeks, grafts 11 
were retrieved for further analysis. H&E staining revealed implants were well integrated into the 12 
host parenchyma, without evidence of significant fibrosis / inflammation whilst neo 13 
vascularization had successfully occurred between host and donor tissues (Fig. 6E and 14 
Supplementary Fig. 20A-B). Histochemical staining with human albumin confirmed the 15 
implanted structures were of human origin, the organoid structure had remained intact and the 16 
presence of human albumin in host serum suggested cells remained functional (Fig. 6F and 17 
Supplementary Fig. 20C-E).  18 
3.5. TGFβ and Hedgehog Signalling Pathways are important for organoid formation  19 
To identify signalling pathways involved in the orchestration of hepatic organoid formation, 20 
gene set enrichment analysis was performed as described before. The top 15 gene sets uniquely 21 
enriched in the ICC were related to metabolic/ biosynthetic and inflammatory/ immune related 22 
processes (Fig. 7A). The enrichment of bile acid metabolism, xenobiotic metabolism, fatty acid 23 
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metabolism, heme metabolism and cholesterol homeostasis are encouraging signs of liver-1 
specific organogenesis. Notably, three highly conserved developmental pathways were identified 2 
through this analysis – hedgehog, notch and TGFβ. To confirm their functional relevance, we 3 
treated organoids with small molecule inhibitors of hedgehog (Cyclopamine – CYC, 0.2µM), 4 
notch (DAPT, 10µM) and TGFβR-1 (RepSox, 12.5µM) and characterized the resultant effects on 5 
organoid formation. Morphological observations were also correlated with RT-qPCR evaluation 6 
of direct transcriptional targets for each signalling pathway (Fig. 7B). Cells managed to establish 7 
Phase I morphology (where cells lined up the surface of ICC) regardless of the treatment. 8 
However, cells treated with RepSox and CYC were unable to form typical organoid structures 9 
(Phase II), whilst DAPT treatment appeared to have little effect (Fig. 7C). RepSox treated cells 10 
arrested in Phase I of organogenesis resembling the observations seen with adult hepatocyte and 11 
liver carcinoma cells (Supplementary Fig. 6). CYC treated cells on the other hand, instead of 12 
transitioning into typical organoid structures, formed much smaller clusters that were less 13 
uniform in size and with a rougher surface. The regulatory network analysis on TGFB and 14 
hedgehog signalling pathways revealed several upstream ligands that are significantly up 15 
regulated in IH-ICC over 2D and could potentially serve as the ligand for signalling activation 16 
(Fig. 7D). The activation of these two pathways in IH-ICC were further validated by the 17 
translocation of phopho-SMAD2/3 and zinc finger GLI1 as shown in immunofluorescence 18 
staining (Fig. 7E and Supplementary Fig. 21). To ensure cytotoxicity was not the causal effect, 19 
the selected concentration of each inhibitor used was validated to have had minimal to no 20 
significant impact on cell viability (Fig. 7F). Furthermore, the dramatic change in organogenesis 21 
observed corresponded to a direct pathway effect (Fig. 7G), reduced hepatic gene expression 22 
profile (Fig. 7F), and reduced albumin production rate (Fig. 7H).  23 
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4. Discussion 1 
Human organs exist in an incredible variety of shapes and sizes. Understanding the processes 2 
through which these varied forms arise during development, are maintained in homeostasis or 3 
become perturbed during disease represent some of the most fundamental questions facing us 4 
today in biology. iPSC-derived cells provide an excellent model with which to study such 5 
questions through ex vivo formation of mini organs known as organoids. iPSC-derived organoids 6 
are also highly appealing because they themselves could be used for patient specific disease 7 
modeling and therapy. Here we report a new approach to the generation of iPSC-derived hepatic 8 
organoids, using state of the art bio-engineering technology that by-passes the need for Matrigel 9 
and supporting cell co-culture. Utility of this platform was demonstrated by our findings in 10 
organoids of advanced hepatic function and dependence on key developmental signaling 11 
pathways (Hedgehog and TGFβ).  12 
Ex vivo liver organogenesis is particularly challenging due to the daunting complexity of 13 
the organ’s structure and function. A pivotal breakthrough in this field was made several years 14 
ago by Takebe and colleagues when they generated hepatic organoids by co-culturing iPSC-15 
derived hepatic endoderm, HUVECs and MSCs in Matrigel [1]. Immediate downstream 16 
translational applications are potentially limited however by dependence upon non FDA-17 
compliant materials such as mouse-sarcoma-derived Matrigel and the difficulty of scaling up 18 
production when using multiple cell types (MSCs & HUVECs) [6]. A more recent and equally 19 
exciting organoid generation system, developed by Huch & Clevers [2], is similarly limited by 20 
the need for Matrigel but also by its need for primary tissue. In this study, we therefore sought to 21 
engineer liver organoids free from Matrigel, MSCs, and HUVECs, using a 3D synthetic hydrogel 22 
scaffold and hiPSC-derived hepatic progenitors alone. To that end we developed a 3D scaffold 23 
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called ICC (inverted colloidal crystal) resembling the precise architectural microenvironment 1 
into which the liver diverticulum engages during liver bud formation [15]. Due to the ICC’s 2 
unique bottom-up fabrication approach, we were able to custom engineer ‘cell-matrix’ 3 
interactions through coating the inner lining of the ICC pores with select ECM proteins [15] as 4 
well as custom engineer ‘cell-cell’ interactions through manipulating pore size [8]. These 5 
engineering designs cumulatively sought to recapitulate the extracellular niche sensed by hepatic 6 
progenitors during bud formation. We observed that the initial bud morphology, which we 7 
describe in this study as Phase I organogenesis / budding, could only be achieved when two 8 
critical factors were met. First, presence of a suitable ECM coating to facilitate cell attachment 9 
which otherwise fails due to the bioinert property of the PEG from which the ICC is 10 
manufactured (Fig. 2A-D). Second, seeding into a suitably sized pore, which otherwise forces 11 
cells to clump rather than attach to the scaffold’s architecture if pore sizes are too small (Fig. 2E-12 
H). Importantly, cell condensation (as opposed to cell-ECM engagement) was associated with 13 
down-regulation in hepatic gene expression, lower albumin production rates and failure to 14 
progress to Phase II in which cells lining the ICC self-organize into interconnected clusters to 15 
create a homogenously repeating organoid tissue structure. This series of morphogenic 16 
movements (Phase I  Phase II) was unique to iPSC (IH) and primary (fetal) hepatic progenitors 17 
and did not occur with terminally differentiated adult cells or with cancer cell lines 18 
(Supplementary Fig. 6) [21, 22]. We therefore hypothesize our 3D scaffolds leverage the 19 
intrinsic ability of liver stem / progenitor cells to form organized structures in a manner which 20 
conserves the interaction observed between progenitors and their surrounding niche during 21 
organogenesis / budding [23]. 22 
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As a consequence of this two-phase organogenesis / budding, the ICC engineered 1 
organoids produce structures with progenitor cells at the periphery and more mature cells in the 2 
middle. Such arrangement is consistent with descriptions of early mammalian liver development, 3 
where liver diverticulum progressing from single cell lining to pseudostratified epithelium then 4 
three-dimensional liver bud [25]. This bioengineering approach may therefore provide a useful, 5 
but simplistic model to further our understanding of early liver development (budding) in vivo 6 
(Fig. 3A and B). This configuration is in direct contrast to findings seen with spheroid / cell 7 
condensation culture systems where cells at the periphery are more viable and proliferative than 8 
cells at the core due to hypoxia and DNA damage [26-29]. That difference underscores the 9 
success of the engineering feat achieved here. The fact that liver specific drug metabolism and 10 
disease modelling become upregulated in parallel with these morphogenic changes along with 11 
the capacity of the organoids to integrate, neo-vascularise and survive in vivo emphasizes the 12 
physiological relevance of the tissue created here (Fig. 4 and 5). How such morphogenesis and 13 
zonation is programmed has been a long-standing question in biology. Our initial interrogation 14 
suggests both the TGFβ and hedgehog signalling pathways to be pivotal in this regard. 15 
Hedgehog signalling is particularly interesting in the context of liver zonation because it has 16 
been reported to orchestrate the position of hepatocytes along an oxygen gradient [24]. Our 17 
treatment of progenitors with a hedgehog signalling pathway inhibitor, Cyclopamine, generated 18 
not only smaller but dysmorphic organoids (Fig. 6C and D) and was accompanied by 19 
downregulation of liver function (Fig. 6F and G). These data suggest Hedgehog may be 20 
involved in much more than simple cell positioning therefore.  21 
To our knowledge, this is the first attempt to produce liver organoids using just the 22 
combination of iPSC-derived hepatic progenitors and a synthetic hydrogel. The unique modular 23 
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features of the ICC scaffold will allow study of the complex, combinatorial influences of 1 
physical and chemical signals during liver organogenesis in a physiologically relevant, 2 
dissectible 3D microenvironment. In addition, the scalable structure and clinically compliant 3 
material (PEG) and cell lines [11] used, opens up the possibility of future human therapy. These 4 
results highlight the enormous potential of bioengineered organoids for discovery and 5 
translational science.  6 
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Figure Captions  13 
Fig. 1. Bioengineering liver organoids using ICC scaffold and iPSC-derived hepatic progenitor  14 
(IH). (A) Schematic illustration of ICC fabrication using a range of sacrificial monodispersed 15 
beads and ECM proteins for stem cell niche modulation. (B) Schematic of human iPSC-derived 16 
hepatic progenitors differentiation protocol. (C) Schematic of bioengineering liver organoids 17 
using IH and ICC in three main steps, cell seeding, cell attachment (Phase I) and organoid 18 
formation (Phase II). Confocal micrographs of human fetal liver cells (Fetal; CTNNB green; 19 
CK19 red) demonstrating the two-phase organoid formation in Col-I coated ICC with 140µm 20 
pore size. Arrowheads indicate cells lining surface of ICC; asterisks represent cells forming 21 
clusters. Scale bar, 100µm. 22 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
Fig. 2. Characterizing the effects of pore size and ECM proteins on liver organoid formation in 1 
ICC scaffold. (A) Confocal micrographs of IH (CTNNB, green; CK19, red) following seeding 2 
into non-coated (Naked), Fibronectin (Fn), Laminin 521 (Ln-521), and Collagen I (Col-I) coated 3 
ICC’s. (B) Quantification of cellular attachment (confluency) and cluster formation (cluster) 4 
ability seen across different ECM’s during Phase I and II. (C) Cell number relative to initial cell 5 
seeding number in Phase I and II. (D) Albumin secretion rate of IH seeded in different ECM 6 
coated ICC in Phase II (E) Bright field images revealing the morphologies of IH in ICC with 7 
different collagen coated pore sizes (40µm, 60µm, 100µm and 140µm) and the respective (F) 8 
morphological quantitation and (G) relative cell number in Phase I and II. (H) Albumin secretion 9 
rate of IH seeded in ICC with different pore sizes in Phase II. Arrowheads indicate cells lining 10 
surface of ICC; asterisks represent cells forming clusters. Scale bar, 100µm. Mean±sd, N=4. *p< 11 
0.05; **p< 0.005; ***p< 0.0005; ****p<0.0001; ns non-significant. 12 
Fig. 3. Morphological and transcriptomic characterization of IH-ICC organoids. (A) 13 
Histochemical images demonstrating morphogenesis of IH from a single cell layer (Phase I top 14 
panel; scale bar, 100µm) to organoids (Phase II bottom panel; scale bar, 50µm) occurs in 15 
conjunction with differential protein expression of developmental markers CK19 (left), EPCAM 16 
(middle) and ALB (right). (B) Confocal micrographs highlighting upregulated protein expression 17 
of mature (ALB, ASGPR1, COL1) hepatic markers occurs in conjunction with down regulation 18 
of immature (CK19 and AFP) markers during transition of IH from Phase I (top panel; scale bar, 19 
100µm) to Phase II (bottom panel; scale bar, 100µm) organoids. (C) FACS histogram and mean 20 
fluorescence intensity (MFI) analysis demonstrating hepatic maturation kinetics of IH in ICC vs 21 
2D culture (N=4). (D) Differential gene expression (by RT-PCR) of selected genes reveals a 22 
more mature hepatic signature of IH in ICC vs. 2D culture (N=8). (e) Bi-clustering heatmap of 23 
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296 liver-specific genes across different primary (adult & fetal liver) and IH (DE, 2D & ICC) 1 
samples. Samples are linked by the dendrogram above to show the similarity of their gene 2 
expression patterns. Mean±sd, *p<0.05; **p< 0.005; ***p< 0.0005; ****p< 0.0001; ns 3 
nonsignificant. 4 
Fig. 4. The transcriptomic analysis of liver organoid in ICC. (A) Principle component analysis of 5 
RNA-seq data demonstrating the proximity of gene expression variance in 2D plot. (B) Venn 6 
diagrams showing the number of up and downregulated gene in ICC and 2D with respect to DE. 7 
(C) RT-PCR validation on top 18 liver-specific genes identified by RNA-seq analysis (N=3) 8 
Mean±sd. 9 
Fig. 5. Functional validation of organoids. (A) Albumin secretion rate of IH-ICC vs. 2D (N=8). 10 
(B) Basal metabolic activity of Cytochrome P450 isoforms CYP3A4 and CYP2C9 in IH-ICC vs 11 
2D (N=8). RLU, relative luminescence unit. (C) Confocal micrographs showing expression of 12 
hepatocyte polarity markers (MRP2, ZO-1, CD26 and Pan-Cadherin) in IH-ICC organoids. Scale 13 
bar, 50µm. White arrowhead points to apical region. (D) Accumulation of Cholyl-L-lysyl-14 
fluorescein (CLS) in IH-ICC organoids after 40 minutes of CLF incubation followed by 40 15 
minutes of washing. White arrowhead points to the CLF accumulation. (E) Effect of adding 16 
Troglitazone (TGZ) to CLS retention in IH-ICC (N=4). (F) A list of uniquely upregulated genes 17 
in IH-ICC vs 2D that involved in establishment and maintainance of cell polarity. FC, fold 18 
change. (G) The STRING functional network predicted the associations between proteins 19 
(nodes) from regulated genes involved in cell polarity in IH-ICC. The cluster analysis was 20 
performed using KMEANS clustering algorithms. Mean±sd, *p<0.05; **p< 0.005; ***p< 21 
0.0005; ****p< 0.0001; ns nonsignificant. 22 
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Fig. 6. Disease modelling and in vivo transplantation. (A) Heatmap and hierarchal clustering 1 
comparing expression of 12 genes involved in encoding HCV entry and assembly in IH-ICC vs 2 
2D vs primary (adult, fetal) liver. (B) Confocal imaging showing expression of claudin 1 and 3 
occludin in IH-ICC organoids. Scale bar, 100µm. White and red arrowheads point to apical and 4 
lateral regions respectively. (C) HCV expression of IH-ICC vs 2D following infection with HCV 5 
reporter virus expressing secreted GLuc (HCVcc, N=4) or mock infected with knock down 6 
HCVcc (kd-HCVcc, N=3) and subsequently were sampled and washed daily. RLU, relative 7 
luminescence unit. (D) Photograph showing location of surgical pocket formation on murine left 8 
lateral lobe (left) and appearance following IH-ICC transplantation (right). The white dashed line 9 
depicts the capsular incision and the limits of the sub-capsular scaffold implant are shown by the 10 
white arrows. Scale bar 1.5mm. (E) H&E staining of explant reveals neo-vasculature of IH-ICC. 11 
Scale bar, 100µm. (F) Immuno-histochemical staining of explant for human albumin. Dashed 12 
white line indicates the boundary between implant and host liver. Scale bar, 100µm. Mean±sd; 13 
**p<0.005, ****p< 0.0001, nd not detected. 14 
Fig. 7. Mechanisms of organoid formation. (A) Bar chart detailing gene sets uniquely enriched in 15 
IH-ICC over 2D. (B) Gene expression (by RT-PCR) in IH-ICC of selected pathway 16 
transcriptional targets, TGFb, Notch and Hedgehog (Hh) following addition of respective 17 
inhibitors (N=4). (C) Confocal micrographs of IH in Phase II (CTNNB, green; CK19, red) 18 
demonstrating effects of inhibitors on IH-ICC morphogenesis. Morphological quantification of 19 
observations provided on right. (D) Regulatory networks of TGFb (left) and hedgehog (right). 20 
Genes labelled in red and green were identified as significantly up- and down regulated in IH-21 
ICC over 2D. (E)  Confocal micrographs showing translocation of phosphor-SMAD2/3 and 22 
GLI1 in response to TGFb and hedgehog pathway activation in IH-ICC organoids. (F) Cell 23 
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viability in IH-ICC as a consequence of adding each inhibitor as determined by cell activity 1 
(N=8). (G) Gene expression (by RT-PCR) of selected hepatic and biliary markers in IH-ICC 2 
following addition of each inhibitor above (N=4). (H) Effect of inhibitors on IH-ICC hepatic 3 
function by albumin production rate (N=4). Mean±sd, *p< 0.05, **p< 0.005, ***p < 0.0005, 4 
****p<0.0001, ns nonsignificant. 5 
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